Show simple item record

dc.contributor.authorMatthews, Kirstin R.W.
Cuchiara, Maude L.
dc.date.accessioned 2016-07-19T17:04:37Z
dc.date.available 2016-07-19T17:04:37Z
dc.date.issued 2014
dc.identifier.citation Matthews, Kirstin R.W. and Cuchiara, Maude L.. "Gene patents, patenting life and the impact of court rulings on US stem cell patents and research." 9, no. 2 (2014) 191-200. http://dx.doi.org/10.2217/rme.13.93.
dc.identifier.urihttp://hdl.handle.net/1911/90935
dc.description.abstract In June 2013, the US Supreme Court ruled that naturally occurring genes were unpatentable in the caseᅠAssociation for Molecular Pathology v. Myriad Genetics. Up until this decision, Myriad Genetics was the only company in the USA that could legally conduct diagnostic testing forᅠBRCA1ᅠandᅠ2, genes that are linked to familial breast and ovarian cancer. The court case and rulings garnered discussion in public about patenting biological materials. This paper will describe the progression of the Myriad Genetics case, similar US rulings and biological intellectual property policies. In addition, it will discuss the impact of the case on biological patents ヨ specifically those for human embryonic stem cells.
dc.language.iso eng
dc.relation.urihttp://bakerinstitute.org/research/new-patenting-guidelines-needed-biotechnology/
dc.title Gene patents, patenting life and the impact of court rulings on US stem cell patents and research
dc.type Journal article
dc.subject.keywordAMP
BRCA
genes
Myriad Genetics
patents
USPTO
dc.citation.volumeNumber 9
dc.citation.issueNumber 2
dc.contributor.publisher Future Medicine Ltd
dc.type.dcmi Text
dc.identifier.doihttp://dx.doi.org/10.2217/rme.13.93
dc.type.publication post-print
dc.citation.firstpage 191
dc.citation.lastpage 200


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record